Q-GRFT Nasal Spray for Coronavirus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Coronavirus+7 MoreQ-Griffithsin - Drug
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it is safe for humans. The drug will be given to adults through a nasal spray, and they will be monitored for side effects. If the drug is safe, participants will use it for 13 more days. The trial will last for 6-8 weeks total.

Eligible Conditions
  • Coronavirus
  • Safety
  • Pharmacokinetics

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Nebulized Furosemide
1
Zofin
1
Ritonavir

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Approximately 28 days

Approximately 14 days
Mean Change in Brief Smell Identification Test (BSIT) Score
Q-GRFT Concentration from Nares Swab Eluent Collected at 24 Hours After 13 Consecutive Daily Intranasal Applications
Q-GRFT Concentration from Oropharyngeal Swab Eluent Collected at 24 Hours After 13 Consecutive Daily Intranasal Applications
Q-GRFT Concentration from Rectal Swab Eluent Collected at 24 Hours After 13 Consecutive Daily Intranasal Applications
Approximately 24 hours
Q-GRFT Concentration from Nares Swab Eluent Collected at 24 Hours
Q-GRFT Concentration from Nasopharyngeal Swab Eluent Collected at 24 Hours
Q-GRFT Concentration from Oropharyngeal Swab Eluent Collected at 24 Hours
Q-GRFT Plasma Concentration Collected at 24 Hours
Approximately 28 days
Acceptability of the Intranasal Spray
Area Under the Nasopharyngeal Swab Eluent Concentration versus Time Curve of Q-GRFT
Area Under the Plasma Concentration versus Time Curve of Q-GRFT
Approximately 8 weeks
Number of Participants with Related Grade 2 or Higher Adverse Events

Trial Safety

Safety Progress

1 of 3

Similar Trials

2
Nebulized Furosemide
1
Zofin
2
Ritonavir

Trial Design

2 Treatment Groups

Q-GRFT Nasal Spray
1 of 2
Placebo Nasal Spray
1 of 2

Active Control

Non-Treatment Group

50 Total Participants · 2 Treatment Groups

Primary Treatment: Q-GRFT Nasal Spray · Has Placebo Group · Phase 1

Q-GRFT Nasal Spray
Drug
ActiveComparator Group · 1 Intervention: Q-Griffithsin · Intervention Types: Drug
Placebo Nasal Spray
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 28 days

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,085 Previous Clinical Trials
41,141,461 Total Patients Enrolled
Sharon HillierLead Sponsor
1 Previous Clinical Trials
480 Total Patients Enrolled
Sharon L Hillier, PhDPrincipal InvestigatorUniversity of Pittsburgh
10 Previous Clinical Trials
2,183 Total Patients Enrolled

Eligibility Criteria

Age 18 - 55 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a man who has sex with men exclusively and/or sexually abstinent for the past 60 days and agree to remain abstinent for the duration of the study.
You have a negative SARS-CoV-2 test at screening.
You are fully vaccinated for SARS-CoV-2.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top